直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Eli Lilly and Company

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Represented Eli Lilly in two IPRs and on appeal to Federal Circuit.

Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, IPR2014-00693, -00752, PTAB, Judges Green, Prats, Snedden

Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 16-1547, Fed. Cir., Judges Bryson, Moore, Newman

Related Professionals

Mark J. Feldstein, Ph.D.
Partner
Washington, DC
+1 202 408 4092
Email
Mareesa A. Frederick
Partner
Washington, DC
+1 202 408 4383
Email
Yieyie Yang, Ph.D.
Partner
Washington, DC
+1 202 216 5170
Email

Related Practices

Appeals from the PTAB

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Life Sciences

Pharmaceutical

Related Experiences

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Eli Lilly and Company

IntelGenX Corporation v. Eli Lilly and Company; ICOS Corporation

Eli Lilly and Company; ICOS Corporation

Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®

Eli Lilly and Company

Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.

Eli Lilly and Company

When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan

Eli Lilly and Company

Alzheimer's Institute of America, Inc. v. Eli Lilly and Company

Eli Lilly and Company

Eli Lilly and Company v. Actavis Labs. UT Inc.

Eli Lilly and Company

Eli Lilly and Company v. Teva Pharmaceuticals International

Eli Lilly and Company

Sun Pharmaceutical Inds. v. Eli Lilly and Co. 

Eli Lilly and Company

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP